For individuals managing these costs out of pocket, dosing decisions should be made in consultation with a licensed provider based on clinical appropriateness
Patients should contact their GP or diabetes specialist nurse if they experience unexpected changes in blood glucose control, significant gastrointestinal symptoms, or concerns about dietary modifications whilst on GLP-1 therapy

Additional strategies to manage side effects: Eat smaller, more frequent meals rather than large portions Avoid high-fat, greasy, or spicy foods that may exacerbate nausea Stay well hydrated to prevent dehydration and potential kidney problems Eat slowly and stop when you feel comfortably full Consider ginger tea or other natural remedies for nausea (discuss with your pharmacist) When to seek medical advice: Contact your GP or healthcare provider if you experience: Severe, persistent vomiting that prevents adequate fluid intake Signs of dehydration (dark urine, dizziness, reduced urination) which may lead to acute kidney injury Severe abdominal pain , particularly if accompanied by vomiting (potential pancreatitis) Symptoms of hypoglycaemia if taking other diabetes medications Visual changes or eye symptoms , particularly if you have pre-existing diabetic retinopathy New or worsening mood changes , including thoughts of self-harm Persistent side effects that significantly affect your quality of life Rare but serious adverse effects include pancreatitis, gallbladder problems, and thyroid C-cell tumours (observed in animal studies, with uncertain relevance to humans)

Our results are at odds with data published by Mody and collaborators who, in a larger population, found better performance in terms of adherence and persistence to therapy with dulaglutide as compared to OW semaglutide and OW exenatide in a larger population ( This study has strengths and limitations
Unlike pharmaceutical products with regulatory oversight, research peptides vary substantially in purity and accuracy of contents